Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunityArticle Published on 2022-09-082022-11-15 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, [키워드] antibody archive authority Breakthrough infection cellular cellular immunity Coalition Council Delta delta variant early immune response European healthy controls Horizon Human immune response in healthy individual increase in individual Infection Inflammatory mediators inflammatory parameters information interferon gamma median time Mild Neutralizing activity Norway Nucleocapsid proteins omicron Patient Protein RBD Regional Result SARS-CoV-2 sera symptom onset the receptor-binding domain the SARS-CoV-2 university vaccinated individual vaccinated individuals Vaccine vaccine dose Vaccine-induced immunity variant Whole blood [DOI] 10.3389/fimmu.2022.964525 PMC 바로가기
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trialsClinical Trial Published on 2022-08-122022-10-05 Journal: EBioMedicine [Category] SARS, 변종, 임상, 진단, [키워드] adverse event Anti-RBD IgG AstraZeneca baseline Biotechnology Cellular immune response cellular immune responses clinical clinical trial Coalition conducted convalescent serum correlation COVID-19 COVID-19 vaccination COVID-19 vaccine CpG1018 Department domain doses Efficacy finding foundation funding groups humoral immune responses incidence India Innovation Melinda Gate Moderna multicentre NAb neutralising antibody observation Open-label profile Protein subunit randomised randomly divided Receptor-binding domain Registered registry reported safety profile SARS-CoV-2 SARS-COV-2 infection second dose significantly Spike protein the vaccine titre titres Trial Vaccine [DOI] 10.1016/j.ebiom.2022.104217 [Article Type] Clinical Trial
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trialClinical Trial Published on 2022-08-102022-10-06 Journal: The Lancet. Infectious Diseases [Category] SARS, 변종, 진단, [키워드] 1:1 Administered administration adverse event adverse events age amplifying analysed Analysis antibody concentration Antigen assigned available data BMI booster booster dose Breastfeeding Coalition Contraception COVID-19 pandemic diagnosis of COVID-19 dose Efficacy enrolled evaluated event Evidence exclusion geometric mean titre GMT group healthy homologous IgG immune response inactive increase in initial intramuscular Local Matrix-M median Medical conditions Novavax NVX-CoV2373 outcome participant per-protocol per-protocol population phase 2 trial phase 3 study Placebo placebo-controlled pregnant primary endpoint proportion Protein randomisation randomised Randomly reaction reactogenicity receive Recombinant spike protein recruited regimens Registered Safety SARS-CoV SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 vaccine SARS-CoV-2 variant screened serum IgG single booster dose stratified Support the SARS-CoV-2 the vaccine titres Treatment Trial USA vaccination Vaccine variant were excluded women [DOI] 10.1016/S1473-3099(22)00420-0 PMC 바로가기 [Article Type] Clinical Trial
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook Reviews Published on 2022-07-202022-10-05 Journal: Nature reviews. Gastroenterology & hepatology [Category] B형 간염, Fulltext, 바이오마커, 진단, [키워드] antiviral therapy Biomarker Biomarkers causes Clinical practice clinical utility Coalition complementary Course curative develop Disease progression effort HBV HBV disease hepatitis B Hepatitis B virus host response immunological Infection Interpretation knowledge Liver cancer meeting MONITOR participated progression Replication serum biomarker Therapies therapy Treatment Treatment response Vaccine [DOI] 10.1038/s41575-022-00649-z [Article Type] Reviews
Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE – Coalition V): A double-blind, multicentre, randomised, controlled trialResearch article Published on 2022-07-012022-10-05 Journal: The Lancet Regional Health - Americas [Category] 신약개발, 임상, 치료법, [키워드] 1:1 Analysis benefit Brazil Chloroquine Clinical deterioration Coalition complement conducted Controlled trial COPE COVID-19 COVID-19 patient did not reduce double-blind Enrollment events finding form funding hospitalisation Hydroxychloroquine Infection intention-to-treat ITT matching placebo Meta-analysis Mild mITT analysis moderate molecular multicenter multicentre no significant difference non-hospitalised Outpatient participants with SARS-CoV-2 Patient patients with COVID-19 Placebo placebo group positive precluded presenting Primary outcome randomised Randomly RCT receive reducing Registered risk risk factor serology testing Seven Statistical power suggested Support Symptom Treatment treatment allocation Trial use of hydroxychloroquine was performed [DOI] 10.1016/j.lana.2022.100243 [Article Type] Research article
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females남성과 여성에서 ChAdOx1 nCoV-19(AZD1222) 백신에 대한 반응에 대한 탐색적 분석Article Published on 2022-07-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 95% CI Academy adjusted age and sex All participant All participants anti-SARS-CoV-2 anti-Spike IgG AstraZeneca AZD1222 both sexes Brazil Cellular immune response ChAdOx1 ChAdOx1 nCoV-19 Chinese clinical Clinical research clinical trials Coalition Council COVID-19 COVID-19 vaccine COVID-19 vaccines defined dose doses Efficacy endpoints Engineering enrolled Evidence evidence of Exploratory analysis fatigue female females Fever first dose Follow-up foundation funding generate GMR greater headache humoral immune responses immunogenicity immunogenicity data immunological individual Innovation interaction term ISRCTN Linear model linear models log-transformed logistic regression models majority male males Medical Science NAAT nCoV network neutralisation assay NIHR no evidence of nucleic acid nucleic acid amplification nucleic acid amplification test Oxford participant Participants primary endpoint randomised randomised controlled trial reaction reactogenicity receive Registered Regression model reported SARS-COV-2 infection Science Sex Sex-differences shown single-blind South spike IgG Standard dose statistically significant difference Superior symptomatic SARS-CoV-2 infection systemic reaction Telle the primary endpoint titre trial participants vaccination Vaccine vaccine efficacy Vaccines Valley Volunteer [DOI] 10.1016/j.ebiom.2022.104128 PMC 바로가기 [Article Type] Article
Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trialSARS-CoV-2 및 S-Trimer(SCB-2019) COVID-19 백신에 대한 이전 노출이 재감염 위험에 미치는 영향: 무작위 배정, 이중 맹검, 위약 대조, 2상 및 3상 시험Clinical Trial Published on 2022-07-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] 1:1 95% CI addition Alpha assigned attack rates B.1.1.7 B.1.351 B.1.617.2 B.1.621 baseline Beta calculate CEPI Clover Coalition confirmed case COVID-19 COVID-19 infection COVID-19 vaccination COVID-19 vaccine dose double-blind double-blinded Efficacy enrolled Evidence evidence of exposure to FIVE groups hospitalisation Impact injection site pain Innovation IQVIA Lambda Local lowest moderate-to-severe COVID-19 multicentre no evidence of P.1 participant Participants Phase 2 Placebo placebo-controlled placebo-controlled trial Primary outcome Primary outcomes protection Protective randomised Randomly Rate reactogenicity Real-time PCR receive recipients recombinant Reinfection reported response risk SARS-CoV-2 SARS-CoV-2-naïve participants SCB-2019 Secondary analyses secondary analysis Serious Adverse Event Serious Adverse Events severe adverse events severe COVID-19 severity subsequent subset symptomatic systemic adverse event systemic adverse events technology Trial USA vaccination Vaccine vaccine dose vaccine efficacy variant variants Viral variants with COVID-19 [DOI] 10.1016/S1473-3099(22)00144-X PMC 바로가기 [Article Type] Clinical Trial
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trialHIV-1 감염 여부에 관계없이 살고 있는 사람들을 대상으로 한 SARS-CoV-2 재조합 스파이크 단백질 나노입자 백신의 면역원성과 안전성: 무작위, 대조, 2A/2B상 시험Clinical Trial Published on 2022-05-012022-09-12 Journal: The Lancet. HIV [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 1:1 amplification angiotensin-converting enzyme 2 anti-Spike IgG antibody Antiretroviral therapy article assigned baseline clinical Coalition Cohort COVID-19 COVID-19 vaccine death dosage Efficacy and safety ELISA endpoints enrolled enrolment evaluated first vaccination geometric mean titre GMT GMTs HIV-1 HIV-1 viral HIV-negative humoral immune response immunogenicity increased risk individual injection interim analysis intervention group Intramuscular injection less Local Matrix-M Melinda Gate multicentre neutralising antibody titres Novavax NVX-CoV2373 NVX-CoV2373 vaccine observer-blinded occurred PACTR202009726132275 participant Participants paucity of data Placebo placebo-controlled provided randomised Randomly reactive receive Recombinant spike protein Registered registry remained reported safety analysis SARS-CoV-2 SARS-CoV-2 nucleic acid SCR SCRs second vaccination Serious Adverse Event Serious Adverse Events seroconversion rate serostatus South Africa stratified study group Support systemic adverse event the placebo group the vaccine Trial vaccination Vaccine vaccine immunogenicity Volume was used were assessed [DOI] 10.1016/S2352-3018(22)00041-8 PMC 바로가기 [Article Type] Clinical Trial
The Abbott Pandemic Defense Coalition: a unique multisector approach adds to global pandemic preparedness effortsAbbott Pandemic Defense Coalition: 고유한 다중 부문 접근 방식이 글로벌 전염병 대비 노력에 추가Article Published on 2022-04-012022-09-11 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] Abbott APDC approach Coalition Critical detection diagnostics Early detection effort emerging pathogens, virus discovery, surveillance, public health. Epidemiology extension global pandemic Infectious disease infectious disease outbreak Mitigation organizations pandemic pandemic preparedness pathogen Pathogens public health severe SARS severe SARS-CoV-2 Spread Surveillance threat Threats unique virus [DOI] 10.1016/j.ijid.2022.02.001 PMC 바로가기 [Article Type] Article
Adopting an heterologous prime-boost strategy in COVID-19 vaccination: the need for locally generated evidence in AfricaCOVID-19 백신 접종에서 이종 프라임-부스트 전략 채택: 아프리카에서 지역적으로 생성된 증거의 필요성Article Published on 2022-02-182022-09-11 Journal: The Pan African Medical Journal [Category] COVID19(2023년), SARS, 변종, [키워드] access African Alliance approach AstraZeneca booster dose ChAdOx1 ChAdOx1 nCoV-19 clinical trial Coalition country COVAX COVID-19 COVID-19 vaccine COVID-19 vaccines COVID-19-heterologous vaccine database discrimination distribution dose empirical evidence equity Evidence experimental arm generate Heterologous heterologous prime-boost heterologous vaccine immunogenicity in some individual initiative Innovation manuscript Oxford partnership Population prevalence of COVID-19 Prevent prime-boost dose reactogenicity reduced reduction in robust Safety severity vaccination Vaccine variants variants of concern WHO [DOI] 10.11604/pamj.2022.41.148.31620 PMC 바로가기 [Article Type] Article